DK1214416T3 - Anvendelse af en replikationshæmmet adenoviral vektor til fremstilling af et lægemiddel til stimulering af immunreaktionen mod antigen hos CD+ T-celler - Google Patents
Anvendelse af en replikationshæmmet adenoviral vektor til fremstilling af et lægemiddel til stimulering af immunreaktionen mod antigen hos CD+ T-cellerInfo
- Publication number
- DK1214416T3 DK1214416T3 DK00960857T DK00960857T DK1214416T3 DK 1214416 T3 DK1214416 T3 DK 1214416T3 DK 00960857 T DK00960857 T DK 00960857T DK 00960857 T DK00960857 T DK 00960857T DK 1214416 T3 DK1214416 T3 DK 1214416T3
- Authority
- DK
- Denmark
- Prior art keywords
- antigen
- replication
- immune response
- adenoviral vector
- stimulate
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 6
- 102000036639 antigens Human genes 0.000 title abstract 6
- 108091007433 antigens Proteins 0.000 title abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 230000028993 immune response Effects 0.000 title abstract 2
- 230000010076 replication Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000037452 priming Effects 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9922361.2A GB9922361D0 (en) | 1999-09-21 | 1999-09-21 | Generating an immune response to an antigen |
| PCT/GB2000/003601 WO2001021201A2 (en) | 1999-09-21 | 2000-09-20 | Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1214416T3 true DK1214416T3 (da) | 2005-08-29 |
Family
ID=10861351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00960857T DK1214416T3 (da) | 1999-09-21 | 2000-09-20 | Anvendelse af en replikationshæmmet adenoviral vektor til fremstilling af et lægemiddel til stimulering af immunreaktionen mod antigen hos CD+ T-celler |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP1612269A1 (enExample) |
| JP (1) | JP2003509470A (enExample) |
| CN (1) | CN1391609A (enExample) |
| AT (1) | ATE295421T1 (enExample) |
| AU (1) | AU762894B2 (enExample) |
| BR (1) | BR0014138A (enExample) |
| CA (1) | CA2384806A1 (enExample) |
| DE (1) | DE60020136T2 (enExample) |
| DK (1) | DK1214416T3 (enExample) |
| ES (1) | ES2241653T3 (enExample) |
| GB (1) | GB9922361D0 (enExample) |
| WO (1) | WO2001021201A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| JP2003530307A (ja) | 1999-07-06 | 2003-10-14 | メルク・アンド・カンパニー・インコーポレーテッド | ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン |
| US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| JP4654026B2 (ja) * | 2002-05-20 | 2011-03-16 | 独立行政法人科学技術振興機構 | Ｂｃｇワクチンとその利用 |
| EP1553983A2 (en) | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| CN100410382C (zh) * | 2006-08-18 | 2008-08-13 | 上海交通大学医学院 | 一种可诱生细胞免疫应答的共表达载体和真核表达载体 |
| JP5646851B2 (ja) * | 2006-11-17 | 2014-12-24 | ジェネトロニクス，インコーポレイティド | エレクトロポレーション支援ワクチン投与及び追加投与を用いた免疫応答の増強方法 |
| GB0706914D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
| GB0706912D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel viral vaccines |
| CA2699465C (en) * | 2007-09-14 | 2017-11-28 | Institut Pasteur | Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use |
| GB0823497D0 (en) | 2008-12-24 | 2009-01-28 | Isis Innovation | Immunogenic composition and use thereof |
| MX380483B (es) * | 2012-10-28 | 2025-03-12 | Bavarian Nordic As | Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes. |
| EP3595705A1 (en) | 2017-03-15 | 2020-01-22 | Oxford BioMedica (UK) Limited | Method |
| MX2022004484A (es) * | 2019-10-16 | 2022-07-19 | Cancer Research Tech Ltd | Vector para el tratamiento de cancer. |
| EP4444347A1 (en) | 2021-12-07 | 2024-10-16 | Barinthus Biotherapeutics (UK) Limited | Vaccine boost methods and compositions |
| WO2024218165A1 (en) | 2023-04-17 | 2024-10-24 | Barinthus Biotherapeutics (Uk) Limited | Hpv viral vector vaccine |
-
1999
- 1999-09-21 GB GBGB9922361.2A patent/GB9922361D0/en not_active Ceased
-
2000
- 2000-09-20 BR BR0014138-0A patent/BR0014138A/pt not_active Application Discontinuation
- 2000-09-20 CA CA002384806A patent/CA2384806A1/en not_active Abandoned
- 2000-09-20 ES ES00960857T patent/ES2241653T3/es not_active Expired - Lifetime
- 2000-09-20 WO PCT/GB2000/003601 patent/WO2001021201A2/en not_active Ceased
- 2000-09-20 AU AU73024/00A patent/AU762894B2/en not_active Ceased
- 2000-09-20 EP EP05009308A patent/EP1612269A1/en not_active Withdrawn
- 2000-09-20 DE DE60020136T patent/DE60020136T2/de not_active Revoked
- 2000-09-20 JP JP2001524625A patent/JP2003509470A/ja not_active Withdrawn
- 2000-09-20 AT AT00960857T patent/ATE295421T1/de not_active IP Right Cessation
- 2000-09-20 EP EP00960857A patent/EP1214416B1/en not_active Revoked
- 2000-09-20 CN CN00815933A patent/CN1391609A/zh active Pending
- 2000-09-20 DK DK00960857T patent/DK1214416T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| BR0014138A (pt) | 2002-05-21 |
| WO2001021201A3 (en) | 2001-10-18 |
| DE60020136D1 (de) | 2005-06-16 |
| DE60020136T2 (de) | 2006-02-23 |
| CA2384806A1 (en) | 2001-03-29 |
| JP2003509470A (ja) | 2003-03-11 |
| EP1612269A1 (en) | 2006-01-04 |
| EP1214416A2 (en) | 2002-06-19 |
| AU7302400A (en) | 2001-04-24 |
| EP1214416B1 (en) | 2005-05-11 |
| ATE295421T1 (de) | 2005-05-15 |
| AU762894B2 (en) | 2003-07-10 |
| CN1391609A (zh) | 2003-01-15 |
| GB9922361D0 (en) | 1999-11-24 |
| ES2241653T3 (es) | 2005-11-01 |
| WO2001021201A2 (en) | 2001-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB9922361D0 (en) | Generating an immune response to an antigen | |
| Liu et al. | Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation | |
| Babiuk et al. | Adenoviruses as vectors for delivering vaccines to mucosal surfaces | |
| DK0724642T3 (da) | Nukleinsyrevektor, sammensætning indeholdende en sådan vektor og vaccine til immunisering mod hepatitis | |
| DK1187852T3 (da) | Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner | |
| WO2001075087A8 (en) | Subtilisin variants | |
| DE69229476D1 (de) | Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe | |
| WO1995030761A3 (en) | Methods of in vivo gene delivery | |
| ATE312920T1 (de) | Dna immunisierung gegen chlamydia infektion | |
| GB2384709A (en) | Vaccination method | |
| DK1007686T3 (da) | Tuberkulosevaccine | |
| WO1998008542A3 (en) | Compounds and methods for treatment and diagnosis of mycobacterial infections | |
| WO2000053767A3 (en) | Nucleic acid respiratory syncytial virus vaccines | |
| CA2113089A1 (en) | Universal donor cells | |
| JP2003509470A5 (enExample) | ||
| WO2003011331A3 (en) | Materials and methods relating to improved vaccination strategies | |
| DK1272652T3 (da) | Herpesvirus til immunmodulation | |
| ATE319833T1 (de) | Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus | |
| BR9815496A (pt) | Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório | |
| WO1999047558A3 (en) | T cell costimulatory proteins, sequences and uses thereof | |
| BRPI0209416A2 (pt) | Novos vetores de expressão e uso dos mesmos | |
| ATE381351T1 (de) | Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten | |
| WO2002016591A3 (en) | Human transporter family members and uses thereof | |
| WO2003075849A3 (en) | Composition and method for enhancing immune response | |
| WO2000066743A3 (en) | Viral expression vectors |